Novartis (NVS) Receiving Somewhat Favorable Press Coverage, Study Shows

News coverage about Novartis (NYSE:NVS) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Novartis earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.7306887680876 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the media headlines that may have impacted Accern Sentiment’s scoring:

Shares of NVS opened at $75.46 on Thursday. The stock has a market capitalization of $174.88 billion, a P/E ratio of 15.69, a P/E/G ratio of 1.62 and a beta of 0.75. Novartis has a 12-month low of $72.30 and a 12-month high of $94.19. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.91 and a current ratio of 1.17.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Thursday, April 19th. The company reported $1.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.03. The firm had revenue of $12.69 billion for the quarter, compared to analyst estimates of $12.45 billion. Novartis had a net margin of 16.04% and a return on equity of 16.23%. Novartis’s revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.13 EPS. analysts expect that Novartis will post 5.22 earnings per share for the current year.

Several research firms have recently commented on NVS. Zacks Investment Research upgraded Novartis from a “sell” rating to a “hold” rating in a report on Wednesday. ValuEngine lowered shares of Novartis from a “sell” rating to a “strong sell” rating in a report on Monday. Credit Suisse Group upgraded shares of Novartis from an “underperform” rating to a “neutral” rating in a report on Friday, May 25th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novartis in a report on Monday, April 9th. Finally, Deutsche Bank restated a “neutral” rating on shares of Novartis in a report on Tuesday, April 10th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has assigned a buy rating to the company’s stock. Novartis currently has a consensus rating of “Hold” and an average target price of $89.81.

In other Novartis news, major shareholder Institutes For Biomed Novartis purchased 766,666 shares of the business’s stock in a transaction on Monday, April 23rd. The shares were bought at an average cost of $15.00 per share, for a total transaction of $11,499,990.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.01% of the stock is currently owned by insiders.

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

Insider Buying and Selling by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply